Liver function remains normal after taking Erdafitinib/Bocco for three years

Erdafitinib (Erdafitinib) is an oral FGFR-targeted inhibitor, mainly used to treat advanced urothelial cancer (bladder cancer) carrying FGFR mutations or amplifications. Its safety and tolerability are the focus of clinical attention, especially the impact of long-term medication on liver function. Compared with chemotherapy drugs, targeted drugs often have relatively controllable liver toxicity, but there is still the possibility of elevated liver enzymes, and liver function needs to be monitored regularly.

Long-term observation shows that when some patients continue to use erdafitinib for three years or more, liver function can still be maintained within the normal range. This is closely related to the metabolic characteristics of the drug: Erdafitinib is mainly metabolized by the liver, but it selectively targets the FGFR signaling pathway, reducing direct toxicity to liver cells. In addition, clinical guidelines recommend that blood routine and liver function tests, including ALT, AST, total bilirubin and other indicators, should be performed monthly during treatment, so as to promptly detect drug-related liver function abnormalities and adjust the dose or temporarily discontinue the drug according to the situation.

It should be noted that each patient's liver tolerance is different, and underlying liver function abnormalities, concomitant medications, or a history of liver disease may increase the risk of long-term medication. Therefore, even if some patients have normal liver function after taking medication for three years, it cannot be generalized. Individualized management and close monitoring are key to ensuring long-term medication safety. Some doctors will adjust the dose in a timely manner based on the patient's blood drug concentration and clinical response to ensure efficacy and reduce the risk of abnormal liver function.

In short, erdafitinib has shown good long-term liver function safety in clinical practice. Some patients can maintain normal liver function after continuous use for many years. However, the monitoring protocol still needs to be strictly followed to ensure the safety and effectiveness of long-term use of the drug.

Reference materials：https://www.balversa.com/